Navigation Links
Genetic abnormalities in benign or malignant tissues predict relapse of prostate cancer

Philadelphia, PA, May 7, 2012 While active monitoring of serum prostate specific antigen (PSA) levels in men over 50 has greatly improved early detection of prostate cancer, prediction of clinical outcomes after diagnosis remains a major challenge. Researchers from the University of Pittsburgh School of Medicine have found that a genetic abnormality known as copy number variation (CNV) in prostate cancer tumors, as well as in the benign prostate tissues adjacent to the tumor and in the blood of patients with prostate cancer, can predict whether a patient will experience a relapse, and the nature of the relapse aggressive or indolent. Their report is published in the June issue of The American Journal of Pathology.

Copy number variations are large areas of the genome with either duplicated or missing sections of DNA. "Our analysis indicates that CNV occurred in both cancer and non-cancer tissues, and CNV of these tissues predicts prostate cancer progression," says lead investigator Jian-Hua Luo, MD, PhD, associate professor in the Divisions of Molecular and Cellular Pathology, and Anatomic Molecular Pathology, Department of Pathology, University of Pittsburgh School of Medicine. "Prediction models of prostate cancer relapse, or of the rate of PSA level increase after surgery, were generated from specific CNV patterns in tumor or benign prostate tissues adjacent to cancer samples."

To detect the abnormalities, scientists conducted a comprehensive genome analysis on 238 samples obtained from men undergoing radical prostatectomy: 104 prostate tumor samples, 85 blood samples from patients with prostate cancer, and 49 samples of benign prostate tissues adjacent to a tumor. A third of the samples were from patients exhibiting recurrence with a PSA level increasing at a rapid rate, doubling in less than four months (rapid increases are associated with lethal prostate cancer); a third from patients exhibiting recurrence with a PSA level increasing at a slow rate, doubling time greater than 15 months; and a third with no relapse more than five years after surgery. Three commercially available prostate cancer cell lines were also tested to validate the results.

Deletions of large segments of specific chromosomes occurred with high frequency, whereas amplification of other chromosomes occurred in only a subset of prostate cancer samples. Similar amplification and deletion of the same regions also occurred in benign prostate tissue samples adjacent to the cancer. Prostate cancer patients' blood was found to contain significant CNVs. Most were not unique and overlapped with those of prostate cancer samples.

Using gene-specific CNV from tumor, the model correctly predicted 73% of cases for relapse and 75% of cases for short PSA doubling time. The CNV model from tissue adjacent to the prostate tumor correctly predicted 67% of cases for relapse and 77% of cases for short PSA doubling time. Using median-size CNV from blood, the genome model correctly predicted 81% of the cases for relapse and 69% of the cases for short PSA doubling time.

Dr. Luo notes that there are several potential clinical applications using CNV tests. "For a patient diagnosed with prostate cancer, CNV analysis done on blood or normal tissues would eliminate the need for additional invasive procedures to decide a treatment mode. For a patient already having a radical prostatectomy, CNV analysis on the tumor or blood sample may help to decide whether additional treatment is warranted to prevent relapse. Despite some limitations, including the need for high quality genome DNA, CNV analysis on the genome of blood, normal prostate, or tumor tissues holds promise to become a more efficient and accurate way to predict the behavior of prostate cancer."


Contact: David Sampson
Elsevier Health Sciences

Related medicine news :

1. Some women may be genetically predisposed to smoking-related hot flashes
2. Genetically modified T cell therapy shown to be safe, lasting in decade-long study of HIV patients
3. Moffitt researcher awarded GE grant to develop tool to detect breast cancer metastasis genetic risks
4. Research Gets Closer to Genetic Roots of Glaucoma
5. Genetic variants, tobacco exposure and lung cancer risk
6. Study of half siblings provides genetic clues to autism
7. Certain Genetic Regions May Be Tied to Osteoporosis
8. Head, Body Lice Are Genetically Very Similar
9. 2 genetic deletions in human genome linked to the development of aggressive prostate cancer
10. IntegraGen launches ARISk test, a genetic screening tool for autism in high-risk children
11. Genetic causes found in nearly 1 in 5 patients with dilated cardiomyopathy heart failure
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... e-con Systems Inc., a ... announced See3CAM_CU40, the industry’s first RGB-IR pixel format camera with a USB ... member of e-con’s See3CAM family of UVC USB 3.0 cameras, is based on the ...
(Date:10/13/2015)... Boston, MA (PRWEB) , ... October 13, 2015 , ... ... mortar of the body, including muscle, bone, and blood. But how much protein does ... more complicated than it might seem, according to the October 2015 issue of ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... Illinois with more than 59,000 emergency department visits per year, today announced the ... T-System, to help improve clinical, operational and financial outcomes. , In ...
(Date:10/13/2015)... ... 2015 , ... World Patent Marketing , a vertically integrated manufacturer and ... helps people in clearing snow away from the streets and driveways. , "The Snowplowing ... year," says Scott Cooper, CEO and Creative Director of World Patent Marketing and ...
(Date:10/13/2015)... ... 13, 2015 , ... Thermi, an award-winning and innovative aesthetic ... the latest development, ThermiVa® temperature controlled radiofrequency to the medical community. , ... Gynecology and a pioneer in the field of laparoscopy. On June 22, 1988, ...
Breaking Medicine News(10 mins):
(Date:10/12/2015)... HOUSTON , October 13, 2015 ... will be operating in a non-clinical capacity. --> ... will be operating in a non-clinical capacity. --> The ... recently completed installation of the first high field (1.5 Tesla) MRI-guided ... early next year, the system will be operating in a non-clinical ...
(Date:10/12/2015)... , Oct. 12, 2015 ... the setbacks and the needs of the medical membrane ... of membrane devices within the different medical membrane devices ... blood microfilters/apheresis systems and membrane diagnostic devices. - Gain ... in this market. --> Use this report ...
(Date:10/12/2015)... SAN DIEGO and CRANBURY, N.J. ... firm Robbins Arroyo LLP announces that a ... U.S. District Court for the District of New Jersey.  ... Therapeutics, Inc. (NASDAQGM: FOLD) violated the Securities Exchange Act ... 2015, by making materially false and misleading statements about ...
Breaking Medicine Technology: